Amarantus In-licenses Levadopa-induced Dyskinesia Phase 2b-ready Eltoprazine from PGI Drug Discovery


(January 15, 2014) - Amarantus Bioscience Holdings, a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, announced that it has completed the in-licensure of Eltoprazine from PGI Drug Discovery LLC. Amarantus expects to initiate a Phase 2b clinical trial for the treatment of Levadopa-Induced Dyskinesia associated with Parkinson's Disease in 2014 with Eltoprazine. Read more...

Click for a printer friendly version

Back to top